Takeda Oncology: Decades of Leadership in Oncology | Takeda Oncology
Decades of Leadership in Oncology
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
Takeda Provides Update on EXKIVITY® (mobocertinib)
Discovering and developing innovative therapies to deliver potentially transformative treatments
Technological advances continue to push the boundaries of what's possible. Takeda's Teresa Bitetti discusses how we are leveraging these tools for cancer patients.